Fang, A., et al. A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann-Sträussler-Scheinker disease mutation. Acta Neuropathol, 2026 Apr 17, 151(1):41. PMID: 41995880
This paper introduces a novel, structure-based prion vaccine that effectively targets the infectious form of the prion protein (PrP^Sc) by mimicking its disease-specific ...
Read More
Sia, Z.R., et al. Preparing Adjuvanted Nanoliposomes for Applications Toward Recombinant Influenza Vaccine Development. Bio Protoc, 2026 Apr 5, 16(7):e5662. PMID: 41971165
This paper, closely related to the previous one, presents a novel platform for developing recombinant influenza vaccines using adjuvanted nanoliposomes that incorporate s...
Read More
Li, Q., et al. Quillaja saponaria fraction QS-18 as an adjuvant for liposomal seasonal influenza vaccines. NPJ Vaccines, 2026 Apr 28, PMID: 42049779
This study presents a pioneering evaluation of QS-18, an abundant fraction from Quillaja saponaria, as a vaccine adjuvant within liposomal formulations for seasonal influ...
Read More
Gotham, D., et al. Understanding adjuvant supply chains for new TB and malaria vaccines. Vaccine, 2026 Apr 22, 82:128609. PMID: 42025104
This paper provides a comprehensive analysis of the global supply chain for Quillaja-derived saponin adjuvants, notably QS-21, which are pivotal components in several rec...
Read More
Padilla, L., et al. The challenge of one billion adjuvanted vaccine doses: evaluating scalability, sustainability, and supply capacity of Quillaja saponin QS-21 for large-scale vaccine demand. Front Immunol, 2026 Apr 17, 17:1813847. PMID: 42079571
This original paper from Desert King provides a comprehensive evaluation of the scalability, sustainability, and supply capacity of QS-21, a highly potent saponin adjuvan...
Read More
Bai, D., et al. Impact of Side Chain Structure and Aglycon Carbonyl Group on the Immunostimulatory Activities of Semisynthetic Saponin Adjuvants. ACS Pharmacol Transl Sci, 2026 Feb 20, 9(3):706-715, PMID: 41852640
The saponin QS-21, derived from Quillaja saponaria, has been clinically successful in vaccines due to its ability to elicit robust humoral and cellular immunity, exemplif...
Read More
Luo, Z., et al. Developing a Next-Generation Vaccine Adjuvant System through Rational Design to Alleviate AS01 Adjuvant Deficiency. J Med Chem, 2026 Mar 19, PMID: 41855509
This research addresses the critical need to improve vaccine adjuvants, which are essential for enhancing immune responses in subunit vaccines. While AS01 has demonstrate...
Read More
Bundi, C.K., et al. B and T cell responses to pre-erythrocytic R21/Matrix-M and blood- stage RH5.1/Matrix-M malaria vaccines in endemic settings. Front Immunol, 2026 Mar 2, 17:1743327, PMID: 41846927
Malaria remains a major global health challenge, particularly in endemic regions where effective vaccines are critically needed. Recent advances include the development ...
Read More